Cat. No.: HY-W008491

TK-112690

Avis client

Based on 1 Customer Validation

TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC₅₀ of 12.5 μM and human small intestinal UPase with an IC₅₀ of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.91%
CAS No.: 22423-26-3
Formule: C₁₀H₁₂N₂O₅
Masse moléculaire:240.21

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

TK-112690 Chemical Structure

CAS No.: 22423-26-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vivo
- Essai clinique
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vivo

TK-112690 (10-30 mg/kg, i.p., 3 h before and after methotrexate (HY-14519) on Days 2-3, 4 weeks) mitigates methotrexate (MTX) (HY-14519)-induced weight loss in LPS (HY-D1056)-treated C57BL/6 mice^[2].
TK-112690 (60 mg/kg, i.p., 3 h before and after MTX on Days 2-4, 7 days) reduces MTX-induced mucosal permeability loss in C57BL/6 female mice^[2].
TK-112690 (120 mg/kg, i.p., detected at 0.08-12 h post-dose) increases plasma uridine concentration in CD-1 female mice^[2].
TK-112690 (667-3000 mg/kg/day, continuous s.c. infusion via osmotic pumps for 24-72 h) elevates plasma uridine (UR) concentration in a linear manner in BDF-1 mice^[3].
TK-112690 (60 mg/kg, i.p., twice daily with 6-8 h interval on Days 7-20) reduces pulmonary fibrosis in C57BL/6 mice with Bleomycin (HY-108345)-induced fibrosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice^[2]
Dosage:

10, 30 mg/kg
Administration:

i.p., 3 h before and after methotrexate (HY-14519) on Days 2-3, 4 weeks
Result:

Mitigated MTX-induced weight loss in LPS-treated C57BL/6 mice.

Animal Model:

C57BL/6 mice^[2]
Dosage:

120 mg/kg
Administration:

i.p., detected at 0.08-12 h post-dose
Result:

Reduced MTX-induced mucosal permeability loss in C57BL/6 female mice.

Animal Model:

CD-1 female mice^[2]
Dosage:

120 mg/kg
Administration:

i.p., detected at 0.08-12 h post-dose
Result:

Increased plasma uridine concentration in CD-1 female mice.

Animal Model:

BDF-1 mice^[3]
Dosage:

667, 833, 3000 mg/kg/day
Administration:

s.c. infusion via osmotic pumps for 24-72 h
Result:

Elevated plasma uridine (UR) concentration in a linear manner in BDF-1 mice.

Animal Model:

C57BL/6 mice^[3]
Dosage:

60 mg/kg
Administration:

i.p., twice daily with 6-8 h interval on Days 7-20
Result:

Reduced pulmonary fibrosis in C57BL/6 mice with Bleomycin (HY-108345)-induced fibrosis.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 22423-26-3
Appearance Solid
Masse moléculaire 240.21
Formule C₁₀H₁₂N₂O₅
Color White to off-white
SMILES

CC(C1=O)=CN(C2=N1)[C@@]3([H])[C@](O2)([H])[C@@](O)([H])[C@@](O3)([H])CO
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

H₂O : ≥ 100 mg/mL (416.30 mM)

DMSO : 50 mg/mL (208.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1630 mL

20.8151 mL

41.6302 mL

5 mM

0.8326 mL

4.1630 mL

8.3260 mL

10 mM

0.4163 mL

2.0815 mL

4.1630 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (20.82 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (20.82 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (20.82 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Strefeler A, et al. Nucleosides are overlooked fuels in central carbon metabolism. Trends Endocrinol Metab. 2024 Apr;35(4):290-299. [Content Brief]

[2]. William A. Garland, et al. Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same. US 9,382,287 B2. United States Patent and Trademark Office (USPTO). Jul. 5, 2016.

[3]. William A. Garland, et al. Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease. US 2025/0222000 A1. United States Patent and Trademark Office (USPTO). Jul. 10, 2025.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.1630 mL	20.8151 mL	41.6302 mL	104.0756 mL
	5 mM	0.8326 mL	4.1630 mL	8.3260 mL	20.8151 mL
	10 mM	0.4163 mL	2.0815 mL	4.1630 mL	10.4076 mL
	15 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9384 mL
	20 mM	0.2082 mL	1.0408 mL	2.0815 mL	5.2038 mL
	25 mM	0.1665 mL	0.8326 mL	1.6652 mL	4.1630 mL
	30 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4692 mL
	40 mM	0.1041 mL	0.5204 mL	1.0408 mL	2.6019 mL
	50 mM	0.0833 mL	0.4163 mL	0.8326 mL	2.0815 mL
	60 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	80 mM	0.0520 mL	0.2602 mL	0.5204 mL	1.3009 mL
	100 mM	0.0416 mL	0.2082 mL	0.4163 mL	1.0408 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

TK-112690

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-Pulmonary Fibrosis Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

3D Diverse Fragment Library

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

TK-112690

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-Pulmonary Fibrosis Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

3D Diverse Fragment Library

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

TK-112690 Related Classifications

HY-W008491 Related Classifications